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DOI: 10.1039/c0md00251hErythromycin B, an acid-stable co-metabolite of the important antibiotic erythromycin A, differs from
erythromycin A only in the absence of a hydroxyl group at C12, yet it has never been licensed for
clinical use. We describe an NMR-based analysis of the conformation of erythromycin B, both free in
aqueous solution and when weakly bound to bacterial ribosomes and show that it is conformationally
similar to erythromycin A. The antibacterial activity of erythromycin B is shown to be similar to that of
erythromycin A, but after acid-treatment, resembling exposure to the stomach, erythromycin B
substantially retains antibacterial activity, whereas erythromycin A does not.Introduction
Erythromycin B (1) is a biosynthetic co-metabolite of the clini-
cally important macrolide antibiotic erythromycin A (2).1 The
drug was first isolated from fermentation broths of Saccha-
ropolyspora erythraea in 1954,2 and its structure was proposed in
1957.3 Like erythromycin A and its derivatives, the drug is basic,
relatively insoluble in water but soluble in organic solvents.
In common with other macrolide antibiotics, erythromycin B
shows a broad range of activity against Gram-positive bacteria
and limited activity against Gram-negative bacteria. It exerts its
antibacterial activity by binding to the 50S subunit of the
bacterial ribosome, thereby inhibiting microbial protein
synthesis.4,5 Against a range of both Gram-negative and Gram-aSchool of Pharmacy and Pharmaceutical Sciences, University of
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This journal is ª The Royal Society of Chemistry 2011positive bacteria erythromycin B is reported to have comparable6
or slightly lower7 potency than erythromycin A.
Erythromycin A is more abundant and therefore easier to
isolate than erythromycin B. Presumably because of the success
of erythromycin A, erythromycin B has been largely neglected by
the pharmaceutical industry. Recently, however, we have high-
lighted a number of advantages of erythromycin B over eryth-
romycin A. Firstly, it is much more stable to acid, because it is
unable to cyclize in a 12,9-direction; erythromycin A undergoes
facile formation of the spiro-6,9:12,9-cyclized anhydroery-
thromycin A, which has little or no antibacterial activity.7 The 20-
esters of erythromycin B are also much more stable to acid than
those of erythromycin A. This finding is potentially important in
paediatric medicine, in which 20-esters serve as pro-drugs.
Finally, we have been able to derivatize erythromycin B to give
pro-pro-drugs, for example erythromycin B enol ether ethyl
succinate (3), which are almost insoluble in the medicine bottle
and therefore unable to hydrolyse to yield the vile-tasting
erythromycin free base. Compound 3 is activated in two stages,
as shown in Scheme 1, to yield erythromycin B.8
These findings suggest that erythromycin B has potential as an
independent entity in paediatric medicine, and prompted us to
return to the fundamental chemistry of this drug, in particular to
determine its conformation in free aqueous solution and when
weakly bound to bacterial ribosomes.
It has previously been postulated that erythromycin A and
some of its derivatives bind to the ribosome of Escherichia coli in
a two stage process. A strong binding interaction has been
detected by equilibrium dialysis and related techniques,9–11 and
more recently characterized in detail by X-ray crystallography.12
A weak interaction has been characterized as a fast exchange
process by NMR spectroscopy.13,14 Unlike the strong interaction,
the weak interaction appears to be magnesium independent.15 It
has also been shown that for erythromycin A, the E. coli ribo-
some tautomerically recognizes and preferentially binds to the
9-ketone form of the drug.14Med. Chem. Commun., 2011, 2, 331–336 | 331
Scheme 1 Activation of erythromycin B enol ether ethyl succinate to erythromycin B.
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View OnlineWe now report the full assignments of the 1H and 13C NMR
spectra of erythromycin B in organic and aqueous solutions.
These assignments have allowed us to determine the conforma-
tional mix of the molecule in free aqueous solution and when
bound (weakly) to the bacterial ribosome.
Results
Assignments of the 1H and 13C NMR spectra in aqueous solution
One dimensional 1H, DQF-COSY and tnTOCSY spectra were
obtained using a 4 mM solution of erythromycin B in phosphate-
buffered D2O. A saturated solution (20 mM) was used to
obtain gradient HMBC and HMQC spectra.
The one-dimensional 1H spectrum (Fig. 1 Supplementary
Data†) showed immediately that, in aqueous solution, erythro-
mycin B exists overwhelmingly as a single isomer. Both eryth-
romycins A and C (a biosynthetic precursor of erythromycin A in
which C80 0 bears OH instead of OCH3) form mixtures of 9-
ketone and 12,9-hemiacetal in aqueous solution, and show
characteristic doubling of each signal in the 1H NMR spectrum.
The lack of the 12-OH prevents this in erythromycin B; the
formation of the 6,9-hemiacetal is perfectly possible, but the
presence of a single set of signals in the 1H NMR spectrum
indicate that it is unfavoured.
The full assignments of the 1H and 13C spectra of erythromycin
B and a description of the assignment process are given in the
Supplementary Data.†
The free solution conformation of erythromycin B: The ROESY
spectrum
Crystal structures of macrolide antibiotics have revealed
a tendency for the molecules to adopt one of two distinct
conformations, and several solution studies have led to similar
conclusions. Conformational analyses of erythromycin A 9-
ketone in CDCl3
16 and aqueous solutions17 suggest that, in both
cases, the drug adopts predominantly the folded-out conforma-
tion, which is characterized by the close approach of H4–H11,
H5–H318, H8–H318 and H315–H316. The folded-in conforma-
tion has been identified from the crystal structure of diri-
thromycin18 and is characterized by the close approach of H3–
H8, H3–H11, H4–H318 and H316–H317. More recently, a third,
intermediate conformation has been identified from analysis of
the solution structure of erythromycin A 9-ketone. This
conformation retains many of the same characteristics as the332 | Med. Chem. Commun., 2011, 2, 331–336folded-out conformer, but is distinct owing to the close approach
of H8–H11 so that the orientation of H8 is endo rather than exo
to the macrolide ring, hence we term this the 8-endo-folded-out
erythromycin 9-ketone.17
Many previous studies of the conformations of macrolide
antibiotics have made use of the 1H nuclear Overhauser effect
(NOE) NMR experiment as the main means of obtaining
conformational data.19–21 However, this method can be prob-
lematic when studying molecules of an intermediate size in
aqueous solutions. At operating frequencies of 500–600 MHz,
NOEs for erythromycins are close to zero and either slightly
positive or negative. These effects make even semi-quantitative
analysis of NOESY spectra unreliable when interpreting cross-
peaks in terms of internuclear distances. We therefore chose to
use the rotating frame Overhauser effect experiment,22 in which
all the Overhauser signals are positive. When the spin-lock field
and mixing time are adjusted accurately, artefacts are minimized
and good data are obtained.
The ROESY spectrum of erythromycin B in phosphate buff-
ered D2O (mixing time 250 ms) is shown in Fig. 1A. The cross-
peaks were designated very small, small, medium or large and the
corresponding connectivity table is shown in Table 2 (top) of the
Supplementary Data.† Known internuclear distances (e.g.
H2‘‘proR-H2’’proS, H4–H317) were used to predict internuclear
distances for very small (3.5 1.5A), small (2.5 1.0A), medium
(2.3  0.5 A) and large (2.0  0.4 A) cross-peaks. Medium H4–
H11, H5–H318 and H8–H318 cross-peaks suggest that the folded-
out conformation is highly represented in the solution, and H3–
H8, H3–H11 and H316–H317 signals (indicative of the folded-in
conformation) are absent. A small H8–H11 cross-peak suggests
that the 8-endo-confimation might be represented. Curiously, no
H315–H316 cross-peak was seen, although this had been found in
folded-out clarithromycin and erythromycin A.19
The experiment was repeated with a mixing time of 500 ms,
with essentially identical results.
The NMR data therefore strongly suggest that erythromycin B
exists exclusively or almost exclusively in the folded-out confor-
mation in aqueous solution. Conformational flexibility leads to
small amounts of the 8-endo-folded-out conformer, but we see no
direct evidence for the presence of the folded-in conformer.Unconstrained and constrained molecular modelling
An initial erythromycin B structure was constructed using
Macromodel version 8.0 and erythromycin A23 as the startingThis journal is ª The Royal Society of Chemistry 2011
Fig. 1 500 MHz NMR spectra of 4 mM erythromycin B in aqueous
solution; A: ROESY spectrum B: TRNOESY spectrum in the presence of
0.48 mM E. coli ribosomes.
Fig. 2 Results of conformational searches on erythromycin B A: folded-
out conformer B 8-endo-folded-out conformer C folded-in conformer.
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View Onlinepoint. The resulting structure was then submitted to an uncon-
strained Monte Carlo conformational search in water, using the
AMBER force field, which is recommended for calculations in
water. The global minimum was a conventional folded-out
conformer with the sugars in the up-up orientation and repre-
sented a very close fit to the ROESY spectrum.
Conformational searching is, at its best, satisfyingly rigorous,
with all conformational space being explored. Macrolides are,
however, rather large for this type of search and a 10,000 step
calculation does not necessarily achieve an endpoint of a global
minimum found 20 times. This calculation found no structure in
which H8 approached H11, despite the presence of an H8–H11
crosspeak in the ROESY spectrum.This journal is ª The Royal Society of Chemistry 2011We therefore constrained the H8–H11 distance to 2.5  0.5 A
and recalculated. The global minimum obtained actually had
slightly lower energy than the folded-out global minimum
(144 vs. 149 kJ mol1), but was clearly a folded-in structure. This
structure has an H3–H8 distance of 2.3 A and an H4–H18
distance of 2.2 A, but neither pair of hydrogens gives rise to
a crosspeak in the ROESY spectrum.
A third calculation involved constraining both H8–H11 and
H4–H11 to 2.5  0.5 A. This yielded the expected 8-endo-folded-
out conformer with an energy of 158 kJmol1, 9 kJ mol1 above
that of the folded-out conformer and consistent with the presence
of this conformer at low abundance in aqueous solution.
The three global minima are shown in Fig. 2 and the full details
of these structures are given in the Supplementary Data.†The conformation of erythromycin B bound to bacterial
ribosomes
Erythromycin A and some of its derivatives take part in a weak
interaction with bacterial ribosomes, which may be detected by
NMR. We now wished to determine whether erythromycin B
could also take part in such an interaction and, if so, to determine
the conformation of the bound drug.
The conformation of the ligand bound in a fast exchange
process to bacterial ribosomes may be determined using the
transferred NOESY (TRNOESY) experiment. In this experi-
ment the ligand is present in a large excess over ribosomes, and
equilibrium exists between free and bound ligand. There is a very
rapid build-up of NOEs in the bound state and this NOE
information is transferred to the free state when the ligand
molecule dissociates from the ribosome. Because NOE build-up
in the free state is very slow, or even absent, it is relatively easy to
choose a mixing time such that all the observable information
pertains to the bound ligand. The resulting NOESY spectrum
has chemical shifts due to the free drug, but NOE information
due to the bound drug. The method is prone to spin-diffusion
artefacts but these can be almost eliminated by the use of fully
deuteriated ribosomes and an appropriate mixing time.Med. Chem. Commun., 2011, 2, 331–336 | 333
Table 1 In vitro minimum inhibitory concentrations of erythromycins A
and B against Staphylococcus aureus ACC 601065 and Streptococcus
pyogenes, and the Gram-negatives Haemophilus influenzae ATC 12699. U
¼ untreated drug, P ¼ drug pre-treated with 0.1 M hydrochoric acid
Minimum Inhibitory Concentrations (mg mL1)
S. aureus S. pyogenes H. influenzae
U P U P U P
Ery A 0.9 >8 0.2 1 2.2 >4
Ery B 0.7 1.4 0.2 0.3 2.3 3.6
Clari 0.6 0.9 0.2 0.3 0.6 1.8
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View OnlineThe transferred NOESY spectrum of erythromycin B (4 mM)
in the presence of E. coli deuteriated ribosomes (0.48 mM –
sufficient to cause an approximate doubling of the low frequency
H315 linewidth) is shown in Fig. 1B. The mixing time was opti-
mized empirically at 75 ms. Table 2 (bottom) of the Supple-
mentary Data shows the connectivity table derived from these
data. Signals were designated very small, small, medium or large
on the basis of the size of the cross-peak, the abundance of
information making a semi-quantitative analysis possible.
Known internuclear distances were again used to predict the
internuclear distances for very small (3.5  1.5 A), small (2.5 
1.0 A) medium (2.3  0.5 A) and large (2.0  0.4 A) cross peaks.
More cross peaks were seen in the TRNOESY than in the
ROESY spectrum of the free drug. This reflects the relative
sensitivities of the two techniques. The maximum TRNOE has
a relative intensity of 1, whereas the ROE has +½. The NOE
build-up is very much faster in the TRNOESY than in the
ROESY experiment, because of the very large size of the drug-
ribosome complex. Most of the extra peaks in the TRNOESY
spectrum were consistent with the structure of the free drug, with
internuclear distances of 3–4 A.
In the TRNOESY spectrum the H11–H8 signal is stronger
than in the ROESY spectrum and signals corresponding to H3–
H8 and H4–H18 are still absent, suggesting strongly that the 8-
endo-folded-out conformer is present at low abundance and the
folded-in conformer undetectable.
Three control experiments were carried out in order to control
for non-specific binding to large molecules in the solution.
Erythromycin B (4 mM) was incubated in the presence of
0.96 mM ribosomes and treated with Rnase-1-AS for four hours
at 30 C. The resulting TRNOESY spectrum (not shown) is
essentially blank, containing only the cross-peaks seen in the
NOESY spectrum of erythromycin B with the same mixing time.
To control for non-specific binding we have generally prepared
ribosomal ‘‘core’’ particles from 50S ribosomal subunits. The
subunits are treated with 2 M lithium chloride solution, as
previously described,24 to remove 12 outer proteins, including
L15.25 Protein L15 has been shown, remarkably, to bind to
erythromycin A in isolation, in the absence of other ribosomal
components.26 It is also essential for the binding of erythromycin
to reconstituted ribosomes.26 Fig. 3 in the Supplementary Data
shows the NOESY spectrum obtained when erythromycin B
(4 mM) was incubated with 0.96 mM LiCl treated 50S cores (a
doubling of the molar amount of ribosomes used above, to
compensate for the reduction in molecular weight). This spec-
trum again shows very few cross-peaks, illustrating clearly that
the binding to whole ribosomes (or to 50S subunits13) that we
observe in the TRNOESY experiment is specific, and not the
result of random interactions with large macromolecular
complexes.
The preparation of ribosomal core particles is a demanding
and time-consuming procedure, requiring density gradient
ultracentrifugation. We sought to simplify our control studies by
treating whole ribosomes with lithium chloride. Surprisingly, this
was unsuccessful. Whereas a single treatment with 1.3 M or 2 M
LiCl was sufficient to prevent 50S subunits from binding in the
NMR experiment, we typically required four treatments to
prevent binding to 70S particles. Excellent TRNOESY spectra
were obtained when 70S ribosomes were treated with lithium334 | Med. Chem. Commun., 2011, 2, 331–336chloride only once or twice. 30S ribosomal subunits do not bind
to macrolide antibiotics in the NMR experiment, whilst 50S
subunits do.13 It seems therefore that the 30S subunits protect the
50S subunits from loss of the proteins involved in weak binding.
Finally, we used 30S ribosomal subunits in place of whole
ribosomes. Macrolide antibiotics are known to bind to the 50S
subunit of the ribosome, and binding to the 30S subunit was
undetectable.
The antibacterial activity of erythromycin B
The NMR results, stability data obtained by us and others7,27 and
our previous pro-drug results,8 suggest strongly that erythro-
mycin B has potential has an independent therapeutic entity.
Because of the uncertainty over erythromycin in vitro antibac-
terial activity,6,7 we revisited this, and included a protocol of acid
exposure to mimic the action of the stomach. Minimum inhibi-
tory concentrations of erythromycins A and B and clari-
thromycin were measured (using a serial dilution method)
against four important opportunistic pathogens, namely the
Gram-positive organisms Staphylococcus aureus ATCC 601065
and Streptococcus pyogenes, and Haemophilus influenzae ATCC
12699 and Burkholderia cepacia (Gram-negative). S. pyogenes
and B. cepacia were lab isolates. The measurements were
repeated using drug that had been pre-treated with 0.1 M
hydrochloric acid for 40 min at 37 C, then neutralized to pH 6.8
with sodium hydroxide solution. The results are shown in Table 1
None of the macrolides was effective against B. cepacia, an
important pathogen in cystic fibrosis with known resistance to
many types of antimicrobial agent (data not shown). Clari-
thromycin was slightly more effective than the two erythromy-
cins in either the untreated or acid-treated form. Untreated
erythromycin B showed comparable activity to erythromycin A.
However, following acid treatment, erythromycin B retained
a large proportion of its activity, the greatest loss being 50% of
activity against S. aureus (1 doubling dilution), whereas eryth-
romycin A showed a significant loss of activiity (ca. 87%) against
both S. aureus and S. pyogenes and 50% against H. influenzae.
Discussion
It is clear from these data that the conformation adopted by
erythromycin B when weakly bound to the bacterial ribosome is
essentially the same as that adopted when the drug is free in
aqueous solution. The folded-out conformation with ‘‘up-up’’
sugars described by Everett and Tyler is preferred in aqueousThis journal is ª The Royal Society of Chemistry 2011
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View Onlinesolution and by the bound drug. Both in the free and the bound
state, the drug retains flexibility in the C6–C9 region, leading to
small amounts of 8-endo-folded-out conformer, but not to the
folded-in conformer. X-ray crystallographic studies by Steitz and
co-workers12 have shown that even in the crystal erythromycin A
retains this folded-out conformation.
The nature of the NMR-detected binding remains unclear.
Recent kinetic analysis suggests that erythromycin (erythro-
mycin A in their study) binds to bacterial ribosomes in a two-
stage process28 suggesting that the first stage of this binding is
detected by NMR. This suggestion does, however, require that
a single ribosome can bind two molecules of erythromycin
simultaneously, one detectable by crystallography, the other by
NMR. We are inclined to the view that the transferred NOESY
experiment detects binding weakened by partial denaturation of
the ribosome. This suggestion is (to a degree) supported by the
observation that the weak binding cannot readily be eliminated
by LiCl treatment of whole ribosomes.
Erythromycin B remains the Cinderella of the macrolide
family, unlicenced for human or veterinary use. Yet, unlike
erythromycin A, it is acid-stable. Unlike clarithromycin, it can be
readily esterified at the 20-position to give pro-drugs with
acceptable solubility for paediatric use. We have described some
simple chemistry that allows the preparation of taste-free pro-
pro-drugs of erythromycin B.8 No other macrolide available at
this time supports this chemistry. We and others have shown that
erythromycin B has similar in vitro antibacterial properties to
erythromycin A and clarithromycin.6,7 In the present paper we
have shown that erythromycin B is conformationally similar to
erythromycin A both in aqueous solution and when bound to
bacterial ribosomes, and that the drug retains antibacterial
activity after acid treatment mimicking the stomach.
Experimental
Erythromycin A, erythromycin B and clarithromycin in their
free-base form were gifts from Dr Warren Mann (Abbot Labo-
ratories, UK), and were used without further purification. 1H
NMR spectra were acquired using a Varian Unity 500 spec-
trometer. 13C NMR spectra were acquired using a Jeol EX 270
spectrometer operating at 67.8 MHz. Spectra were referenced to
TMS (tetramethylsilane) or TSP (3-(trimethylsilyl)-2,2,3,3,-tet-
radeuterio-propionic acid sodium salt) at d 0.0.
The Supplementary Data describes the protocols for the
assignment of signals
ROESY spectra of erythromycin B in phosphate buffered D2O
Solutions of 8–10 mM erythromycin B in 50 mM phosphate
buffered D20, apparent pH 7.4, were routinely used to acquire
ROESY spectra. Mixing times of 250 ms and 150 ms were used
with data matrices of 2048 x1024 complex points and the spectra
were processed using a Gaussian window function. Essentially no
differences in the observed signals were observed with the vari-
ations in mixing time and temperature.
Molecular modelling of NMR spectral data
Conformational analysis of the free solution structure of eryth-
romycin B in phosphate buffered D2O was performed usingThis journal is ª The Royal Society of Chemistry 2011Macromodel version 8 software.29 The crystal structure for [9-(0–
2,5,-dioxahexyl) oxime] erythromycin A hydrate23 was obtained
from the Cambridge Crystallographic database and this was used
to derive the starting structure for erythromycin B manually, the
oxime giving a folded-out conformation. This structure was
minimized using the Truncated Newtonian Conjugate Gradient
method (TNCG) in order to obtain local minima.
Monte Carlo searches using AMBER and MM2 force fields
were then carried out to obtain global minimum structures, with
water solvation. The cross peaks from the ROESY spectra were
designated as very small (3.5  1.5 A), small (2.5  1.0 A),
medium (2.3  0.5 A) or large (2.0 0.4 A), the magnitude of the
constraints being determined empirically by referring to known
interatomic distances within the molecule. The distance
constraints from each ROESY and TRNOESY spectra were
then compared with both global minimum erythromycin B
conformers. Where the global minima did not satisfy all the
NMR data, attention were turned to the higher energy structures
and if no structure satisfying all the NMR data was found
a constrained local minimization (or a restrained Monte Carlo
search where appropriate) was performed to obtain conformers
satisfying constraints which were not satisfied with the global
minima.
TRNOESY spectra of erythromycin B bound to bacterial
ribosomes in phosphate buffered D2O
Solutions of 4 mM erythromycin B in 50 mM sodium phosphate
buffered D2O, apparent pH 7.4, were used throughout. All
spectra were run at 30 C. Mixing times were optimized empir-
ically at 75 or 50 ms. Spectra were acquired with data matrices of
2048 x1024 complex points and were processed with Gaussian
window functions.
Control experiments
The control TRNOESY experiments were conducted with the
same experimental parameters as for the 75 ms TRNOESY
experiment, and were processed in the same manner.
Preparation of whole 70S ribosomes, 30S ribosomal subunits and
50S subunit core particles
Whole 70S ribosomes were prepared as previously described25
from cultures of E.coli MRE 600, and were stored at 20 C for
no longer than 2 weeks in 50 mM phosphate buffered D2O. Fully
deuteriated ribosomes were prepared from cultures of E. coli
MRE 600D30 grown on a minimal medium based upon deu-
teriated sodium succinate and D2O.
The 50S ribosomal subunits were prepared as described,24 and
were used to prepare ribosomal core particles by treatment with
2 M LiCl solution.24 The core particles were stored in phosphate
buffered D2O at 80 C for no longer than 2 weeks, and were
defrosted no more than once.
RNAase treatment of ribosomal solutions
A solution of 4 mM erythromycin B in 50 mM deuteriated
phosphate buffer was prepared and 750 ml was transferred to
a 5 mm NMR tube. To this, 32.6 ml of a 32 mM solution ofMed. Chem. Commun., 2011, 2, 331–336 | 335
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View Onlineribosomes, pre-treated with 2 M lithium chloride,24 was added.
RNase I-AS was added to a final concentration of 1 mg ml1 and
the solution incubated at 37 C for 4 h prior to transferred
NOESY experiments.Broth microdilution minimum inhibitory concentrations
These were estimated according to the National Committee for
Clinical Laboratory Standards guidelines (2000).31 The protocol
is described in full in the Supplementary Data.†Conclusions
Erythromycin B adopts a folded-out conformation both in
aqueous solution and when weakly bound to bacterial ribo-
somes. Like erythromycin A, it retains some flexibility in the C7–
C9 part of the molecule leading to a low abundance of the 8-endo-
folded-out conformer. We speculate, based on the data presented
here, that the weak NMR-detected binding of macrolide drugs to
ribosomes arises from partial denaturation of the macrolide
binding site on the ribosome, rather than from a preliminary
binding. We present further evidence that erythromycin B has
potential as an independent therapeutic compound; in particular,
it retains antibacterial activity after treatment with acid,
mimicking the stomach.Acknowledgements
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